- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06112535
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chad Schaber, PhD
- Phone Number: +44 7864 922346
- Email: chad.schaber@cmrsurgical.com
Study Contact Backup
- Name: Morad Nakhleh, PhD
- Phone Number: +44 7518 295217
- Email: morad.nakhleh@cmrsurgical.com
Study Locations
-
-
-
Liverpool, United Kingdom, L9 7AL
- Recruiting
- Liverpool Head and Neck Centre, ENT Department Liverpool University Hospitals NHS Foundation Trust
-
Contact:
- Jason Fleming, MD PhD
- Phone Number: +44 151 5295259
- Email: jason.fleming@liverpool.ac.uk
-
Sub-Investigator:
- Christopher Loh, MD
-
Sub-Investigator:
- Katharine Davies, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient and disease factors deemed suitable for Robotic-Assisted Trans Oral Robotic Surgery (TORS) procedure using the Versius Surgical System
- Aged 18 or over with signed, written informed consent
- Histologically confirmed squamous cell carcinoma of the oropharynx {UICC/AJCC TNM (7) stage T1-3, N0-N2b / TNM (8) T1-3, N0-1 disease} OR Histologically confirmed squamous cell carcinoma in 1 or more cervical lymph nodes, with no discernible primary tumour (cancer unknown primary)
- Patients considered fit for surgery and potential adjuvant treatment (WHO performance status 0-2)
- Multidisciplinary team (MDT) decision to treat with primary surgery
- Surgical site and anatomical factors allowing access and freedom of operating using Versius Surgical System
Exclusion Criteria:
- T4 tumours, or T1-T3 where transoral surgery is not considered feasible due to anatomy, location, or disease factors; these may include (but not limited to) tumour visualisation, endophytic growth pattern and resulting defect functional concerns
- Disease / anatomical factors limiting access and freedom of operating using Versius Surgical System
- Patients with distant metastatic disease as determined by pre-operative staging
- UICC/AJCC TNM (7) stage N2c-N3 disease; TNM (8) N2-3 disease
- American Society of Anaesthesiologists (ASA) Class IV or above
- WHO Performance status 3 or above
- Unwilling or unable to sign an informed consent form
- Morbid Obesity (BMI ≥40)
- Active pregnancy
- Medical Contraindication for general anaesthesia
- Patient participation in an interventional clinical study within 30 days prior to screening, and up to 45 days post-surgery
- Patients with a history of radiotherapy to the head or neck
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TORS with Versius
|
Transoral robotic surgery (TORS) using Versius Surgical System. Versius is a robot designed to help surgeons perform surgery. It consists of a set of robotic arms: one of the arms has a camera and a light source on it while the other arms each have a small surgical instrument attached at the end. The surgeon controls each of the arms with hand controllers (joysticks) and can perform surgery with them, while seeing the surgical area on a screen in front of him/her. The camera and instruments are inserted into the mouth and throat in order to cut out a cancerous tumour. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of Adverse Events
Time Frame: Up to 30 days post operatively
|
To assess safety of TORS with Versius
|
Up to 30 days post operatively
|
Rate of successful completion of TORS without conversion
Time Frame: Up to completion of surgery
|
To assess efficacy of TORS with Versius by the rate of successful completion of Transoral Robotic Surgery (TORS) without unplanned conversion to other transoral or open techniques
|
Up to completion of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operative time
Time Frame: Up to completion of surgery
|
Time taken to complete surgery, excluding any reconstruction
|
Up to completion of surgery
|
Incidence of Serious Adverse Events
Time Frame: Up to 30 days post operatively
|
Incidence of Serious Adverse Events
|
Up to 30 days post operatively
|
Blood loss
Time Frame: Up to completion of surgery
|
Estimated blood loss during surgery
|
Up to completion of surgery
|
Post-operative analgesic requirements in morphine equivalents
Time Frame: Up to post-surgery discharge (up to 30 days post-surgery)
|
Pain medication taken post-surgery converted to morphine equivalents
|
Up to post-surgery discharge (up to 30 days post-surgery)
|
Length of stay
Time Frame: Up to discharge (up to 30 days post-surgery)
|
Length of post operative stay in hospital
|
Up to discharge (up to 30 days post-surgery)
|
Reoperation
Time Frame: Up to 30 days post operatively
|
Emergency re-operation after initial surgery
|
Up to 30 days post operatively
|
Device deficiencies and user errors
Time Frame: Up to completion of surgery
|
Device deficiencies and user errors
|
Up to completion of surgery
|
Return to oral intake
Time Frame: Up to post-surgery discharge (up to 30 days post-surgery)
|
Amount of time after surgery before oral intake, including nasogastric tube requirement and length of use
|
Up to post-surgery discharge (up to 30 days post-surgery)
|
Pathological margin
Time Frame: Up to 30 days post operatively
|
Final pathological margin of resected specimens (mm)
|
Up to 30 days post operatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jason Fleming, MD PhD, ENT Department Liverpool University Hospitals NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA-00388
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Oropharynx
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditionsUnited States
-
University of ChicagoNational Cancer Institute (NCI)TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the OropharynxUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage I Verrucous Carcinoma of the Oral Cavity | Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage... and other conditionsUnited States
-
Arbeitsgemeinschaft medikamentoese TumortherapieCompletedSquamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditionsAustria
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminatedRecurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma... and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedTongue Cancer | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage III Verrucous Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IVA Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedStage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage IV Squamous... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedHuman Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage III Verrucous Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage... and other conditionsUnited States
-
Joseph CalifanoJohns Hopkins University; NYU Langone Health; Greater Baltimore Medical Center; San Diego Veterans Healthcare System and other collaboratorsCompletedSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Squamous Cell Carcinoma of the OropharynxUnited States
Clinical Trials on Versius Surgical System
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingProstate CancerItaly
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingNeoplasms | Gastric Cancer | Gastrointestinal Cancer | Gastric Neoplasm | Stomach Adenocarcinoma | Gastric Diffuse AdenocarcinomaItaly
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruiting
-
Iqbal AhmedOMNI Medical Services, LLCTerminated
-
Medtronic CardiovascularCompletedAtrial FibrillationUnited States
-
Medtronic Cardiac SurgeryCompletedAtrial FibrillationUnited States
-
Medtronic CardiovascularCompleted
-
Deborah Farr, MDRecruitingBreast Cancer | High Risk of Breast CancerUnited States
-
University Hospital TuebingenRecruiting
-
University Health Network, TorontoRecruiting